June 16, 2014 News by Charles Moore Natalizumab, Other Biogen Idec MS Therapies Featured at Medical Congresses; Company Joins Sailing Sclerosis Foundation Oceans of Hope Project Biogen Idec, a U.S. biotechnology company specializing in therapies for neurological disorders, autoimmune disorders and cancer, has announced that more than 60 company-sponsored presentations highlighting key data from its extensive portfolio of marketed and investigational multiple sclerosis (MS) therapies were featured during two 2014 neurology conferences. The company…
June 5, 2014 News by Maureen Newman Biogen Idec Investigates Tysabri in Secondary-Progressive Multiple Sclerosis Patients Biogen Idec is currently sponsoring a clinical trial evaluating its therapy Tysabri (natalizumab) in patients with secondary-progressive multiple sclerosis. Although relapse-remitting multiple sclerosis is more common and well-researched, the National Multiple Sclerosis Society estimates approximately half of relapse-remitting patients will transition to secondary-progressive within 19 years of diagnosis. The…
